OP19: Classifying perianal fistulising Crohn’s Disease: An expert-consensus to guide decision-making in daily practice and clinical trialsECCO'22Year: 2022
Authors: Geldof, J.(1);Iqbal, N.(2);LeBlanc, J.F.(3);Sawyer, R.(4);Buskens, C.(5);Bemelman, W.(5);Gecse, K.(6);Lundby, L.(7);Lightner, A.L.(8);Danese, S.(9);Spinelli, A.(10);Carvello, M.(10);Faiz, O.(11);Warusavitarne, J.(11);Lung, P.(12);De Looze, D.(13);D’Hoore, A.(14);Vermeire, S.(15);Hart, A.(3);Tozer, P.(16);
(1)UZ Gent, Gastroenterology and Hepatology, Gent, Belgium;(2)St Mark’s Hospital and Academic Institute, Robin Phillips Fistula Research Unit-, London, United Kingdom;(3)St Mark’s Hospital and Academic Institute, IBD unit, London, United Kingdom;(4)St Mark’s Hospital and Academic Institute, patient representative, London, United Kingdom;(5)Amsterdam University Medical Center- Gastroenterology Endocrinology Metabolism Research Institute, Department of Surgery, Amsterdam, The Netherlands;(6)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)Aarhus University Hospital, Department of Surgery- Pelvic Floor Unit, Aarhus, Denmark;(8)Cleveland Clinic, Center for Regenerative Medicine and Surgery Colorectal Surgery Digestive Disease Institute Inflammation and Immunity Lerner Research Institute Center for Immunotherapy, Cleveland, United States;(9)Vita-Salute San Raffaele University- IRCCS Hospital San Raffaele, Milan, Italy;(10)Humanitas University- IRCCS Humanitas Research Hospital, Department of Biomedical Sciences, Milan, Italy;(11)St Mark’s Hospital and Academic Institute, Department of Colorectal Surgery, London, United Kingdom;(12)St Mark’s Hospital and Academic Institute, Radiology department, London, United Kingdom;(13)University Hospital Ghent, Department of Gastroenterology and Hepatology, Ghent, Belgium;(14)University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium;(15)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(16)St Mark’s Hospital and Academic Institute- and Imperial College, Robin Phillips Fistula Research Unit- Department of Colorectal Surgery-, London, United Kingdom;
OP20: Perianal fistulas are characterised by expansion of interleukin-22 producing invariant natural killer T-cells and CD4+ T-cells which drive dysregulation of the extracellular matrixECCO'22Year: 2022
Authors: Constable, L.(1,2);Iqbal, N.(3,4);Cozzetto, D.(1);Hart , A.(3,4);Tozer, P.(3,4);Powell, N.(1);
(1)Imperial College London, Metabolism- Digestion and Reproduction, London, United Kingdom;(2)King's College London, Inflammation Biology, London, United Kingdom;(3)St Mark's Hospital and Academic Institute, Robin Phillips Fistula Research Unit, London, United Kingdom;(4)Imperial College London, Surgery and Cancer, London, United Kingdom;
OP21: COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumabECCO'22Year: 2022
Authors: Alexander, J.(1,2);Kennedy, N.(3,4);Ibraheim, H.(1,2);Anandabaskaran, S.(1,5);Saifuddin, A.(1,5);Castro Seoane, R.(1);Liu, Z.(1);Nice, R.(4,6);Bewshea, C.(4);D'Mello, A.(7);Constable, L.(1);Jones, G.R.(8,9);Balarajah, S.(1,2);Fiorentino, F.(10);Sebastian, S.(11,12);Irving, P.M.(13,14);Hicks, L.(1,2);Williams, H.(1,2);Kent, A.(15);Linger, R.(16);King, R.(16);Parkes, M.(16,17);Kok, K.(18);Patel, K.(19);Altmann, D.(20);Boyton, R.(21);Goodhand, J.(3,4);Hart, A.(5);Lees, C.(8,9);Ahmad, T.(3,4);Powell, N.(1,2);
(1)Imperial College London, Metabolism- Digestion & Reproduction, London, United Kingdom;(2)Imperial College Healthcare NHS Trust, Gastroenterology, London, United Kingdom;(3)Royal Devon and Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(4)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(5)St Marks Hospital and Academic Institute, Gastroenterology, London, United Kingdom;(6)Royal Devon and Exeter NHS Foundation Trust, Biochemistry- Exeter Clinical Laboratory International, Exeter, United Kingdom;(7)Imperial College Healthcare NHS Trust, Medicine & Integrated Care, London, United Kingdom;(8)Western General Hospital - NHS Lothian, Gastroenterology, Edinburgh, United Kingdom;(9)The University of Edinburgh, Centre for Inflammation Research - The Queen’s Medical Research Institute, Edinburgh, United Kingdom;(10)Imperial College London, Department of Surgery and Cancer, London, United Kingdom;(11)Hull University Teaching Hospitals NHS Trust, Gastroenterology, Hull, United Kingdom;(12)University of Hull, Hull York Medical School, Hull, United Kingdom;(13)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(14)King's College London, School of Immunology & Microbial Sciences, London, United Kingdom;(15)King's College Hospital, Gastroenterology, London, United Kingdom;(16)University of Cambridge, NIHR Bioresource, Cambridge, United Kingdom;(17)Cambridge University Hospitals NHS Trust, Gastroenterology, Cambridge, United Kingdom;(18)Bart's Health NHS Trust, Gastroenterology, London, United Kingdom;(19)St George's Hospital NHS Trust, Gastroenterology, London, United Kingdom;(20)Imperial College London, Immunology and Inflammation, London, United Kingdom;(21)Imperial College London, Department of Infectious Disease, London, United Kingdom;
OP22: Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patientsECCO'22Year: 2022
Authors: Lin, S.(1,2);Kennedy, N.A.(1,2);Saifuddin, A.(3,4);Muñoz Sandoval, D.(5);Reynolds, C.J.(5);Seoane, R.C.(6);Kottoor, S.H.(4);Pieper, F.P.(5);Lin, K.M.(5);Butler, D.K.(5);Chanchlani, N.(1,2);Nice, R.(2,7);Chee, D.(1,2);Bewshea, C.(2);Janjua, M.(1,2);McDonald, T.J.(7);Sebastian, S.(8,9);Alexander, J.L.(4,10);Constable, L.(4);Lee, J.C.(11,12,13);Murray, C.D.(11);Hart, A.L.(3);Irving, P.M.(14,15);Jones, G.R.(16,17);Kok, K.B.(18,19);Lamb, C.A.(20,21);Lees, C.W.(16,22);Altmann, D.M.(6);Boyton, R.J.(5,23);Goodhand, J.R.(1,2);Powell, N.(4,10);Ahmad, T.(1,2); CLARITY IBD
(1)Royal Devon and Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(2)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(3)St Marks Hospital and Academic Institute, Gastroenterology, London, United Kingdom;(4)Imperial College London, Metabolism- Digestion and Reproduction, London, United Kingdom;(5)Imperial College London, Infectious Disease, London, United Kingdom;(6)Imperial College London, Immunology and Inflammation, London, United Kingdom;(7)Royal Devon and Exeter NHS Foundation Trust, Biochemistry- Exeter Clinical Laboratory International, Exeter, United Kingdom;(8)Hull University Teaching Hospitals NHS Trust, Gastroenterology, Hull, United Kingdom;(9)University of Hull, Hull York Medical School, Hull, United Kingdom;(10)Imperial College Healthcare NHS Trust, Gastroenterology, London, United Kingdom;(11)Royal Free London NHS Foundation Trust, Gastroenterology, London, United Kingdom;(12)University of Cambridge, Cambridge Institute of Therapeutic Immunology and Infectious Disease- Jeffrey Cheah Biomedical Centre, Cambridge, United Kingdom;(13)The Francis Crick Institute, Genetic Mechanisms of Disease Laboratory, London, United Kingdom;(14)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(15)King's College London, School of Immunology & Microbial Sciences, London, United Kingdom;(16)Western General Hospital- NHS Lothian, Gastroenterology, London, United Kingdom;(17)The University of Edinburgh, Centre for Inflammation Research- The Queen’s Medical Research Institute, Edinburgh, United Kingdom;(18)Royal London Hospital- Barts Health NHS Trust, Gastroenterology, London, United Kingdom;(19)Barts and the London School of Medicine- Queen Mary, Centre for Immunobiology- Blizard Institute, London, United Kingdom;(20)Newcastle upon Tyne Hospitals NHS Foundation Trust, Gastroenterology, Newcastle upon Tyne, United Kingdom;(21)Newcastle University, Translational & Clinical Research Institute- Faculty of Medical Sciences, Newcastle upon Tyne, United Kingdom;(22)University of Edinburgh, Institute of Genetic and Molecular Medicine, Edinburgh, United Kingdom;(23)Royal Brompton Hospital and Harefield Hospitals, Lung Division, London, United Kingdom;
OP23: The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12ECCO'22Year: 2022
Authors: Dignass, A.(1);Rubin, D.(2);Bressler, B.(3);Huang, K.H.(4);Shipitofsky, N.(4);Germinaro, M.(4);Zhang, H.(4);Johanns, J.(4);Feagan, B.(5);Sandborn, W.(6);Sands, B.(7);Hisamatsu, T.(8);Lichtenstein, G.(9);Panes, J.(10);Allegretti , J.(11); QUASAR Investigators
(1)Agaplesion Markus Hospital, Department of Medicine, Frankfurt, Germany;(2)The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(3)University of British Columbia, Division of Gastroenterology, Vancouver, Canada;(4)Janssen Research & Development- LLC, Immunology, Spring House, United States;(5)Western University, Robarts Clinical Trials, Ontario, Canada;(6)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(7)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(8)Kyorin University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(9)University of Pennsylvania, Department of Medicine- Division of Gastroenterology, Philadelphia, United States;(10)Hospital Clínic de Barcelona, IDIBAPS- CIBERehd, Barcelona, Spain;(11)Brigham and Women’s Hospital Crohn’s and Colitis Center, Division of Gastroenterology- Hepatology and Endoscopy, Boston, United States;
OP24: Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 studyECCO'22Year: 2022
Authors: Danese, S.(1);Panaccione, R.(2);Rubin, D.T.(3);Sands, B.E.(4);Reinisch, W.(5);D'Haens, G.(6);Panés, J.(7);Gonzalez, S.(8);Weisel, K.(8);Sahoo, A.(8);Frustaci, M.E.(8);Yang, Z.(8);Sandborn, W.J.(9);Afzali, A.(10);Hisamatsu, T.(11);Andrews, J.M.(12);Feagan, B.(13); on behalf of the GALAXI-1 investigators
(1)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milano, Italy;(2)University of Calgary, Inflammatory Bowel Disease Group, Calgary, Canada;(3)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(4)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(5)Medical University of Vienna, Div. Gastroenterology & Hepatology, Vienna, Austria;(6)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;(7)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Department of Gastroenterology, Barcelona, Spain;(8)Janssen Research & Development- LLC, Immunology, Spring House, United States;(9)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(10)The Ohio State University, Wexner Medical Center, Columbus, United States;(11)Kyorin University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(12)Royal Adelaide Hospital & University of Adelaide, Department of Gastroenterology & Hepatology, Adelaide, Australia;(13)Western University and Alimentiv Inc., Department of Gastroenterology, London, Canada;
OP25: Patients with moderate to severe Crohn’s Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trialsECCO'22Year: 2022
Authors: Ferrante, M.(1);Cao, Q.(2);Fujii, T.(3);Rausch, A.(4);Neimark, E.(5);Song, A.(6);Wallace, K.(6);Kligys, K.(7);Zhou, Q.(8);Kalabic, J.(9);Feagan, B.G.(10);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)Sir Run Run Shaw Hospital- Zhejiang University School of Medicine, Department of Gastroenterology, Hangzhou, China;(3)Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(4)British Hospital, Gastroenterology Department, Buenos Aires, Argentina;(5)AbbVie, Clinical Development, Worcester, United States;(6)AbbVie, Clinical Development, North Chicago, United States;(7)AbbVie, Medical Affairs, Mettawa, United States;(8)AbbVie, Statistics, North Chicago, United States;(9)AbbVie Deutschland GmbH & Co. KG, Clinical Development, Ludwigshafen, Germany;(10)Western University, Robarts Clinical Trials- Robarts Research Institute, London, Canada;
OP26: Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 studyECCO'22Year: 2022
Authors: D'Haens, G.(1);Kobayashi, T.(2);Morris, N.(3);Lissoos, T.(3);Hoover, A.(3);Li, X.(3);Arora, V.(3);Milch, C.(3);Sandborn, W.J.(4);Sands, B.E.(5);
(1)Amsterdam University Medical Centers, Gastroenterology, Amsterdam, The Netherlands;(2)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(3)Eli Lilly and Company, Biomedicines, Indianapolis, United States;(4)University of California San Diego, Gastroenterology, San Diego, United States;(5)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;
OP27: A Phase 1 Study Evaluating the Bioequivalence of the Proposed Commercial and Clinical Formulations of Etrasimod 2mg, and the Effect of Food on the Pharmacokinetics of the Proposed Commercial Formulation in Healthy VolunteersECCO'22Year: 2022
Authors: Lee, C.(1);Ramaiya, A.(1);Tang , Y.(1);Sapone, A.(2);Shan , K.(3);Randle, A.(4);Grundy, J.(1);
(1)Arena Pharmaceuticals- Inc., Nonclinical Dev & Clinical Pharmacology, San Diego, United States;(2)Arena Pharmaceuticals- Inc., Clinical Development, San Diego, United States;(3)Arena Pharmaceuticals- Inc., Biostatistics & Data Mgmt, San Diego, United States;(4)Arena Pharmaceuticals- Inc., Clinical Operations, San Diego, United States;
OP28: A randomized placebo controlled clinical trial with 5-hydroxytryptophan in patients with quiescent Inflammatory Bowel Disease and fatigue (Trp-IBD)ECCO'22Year: 2022
Authors: Truyens, M.(1,2,3);Lobaton, T.(1,3);Peeters, A.(1);Ferrante, M.(4,5);Vermeire, S.(4,5);Bossuyt, P.(6);Pouillon, L.(6);Dewint, P.(7,8);Cremer, A.(9);Peeters, H.(10);Lambrecht, G.(11);Louis, E.(12);Rahier, J.F.(13);Dewit, O.(14);Muls, V.(15);Holvoet, T.(1,16);Vandermeulen, L.(17);Gonzales, G.B.(2,3,18);Laukens, D.(2,3);De Vos, M.(3);
(1)University Hospital Ghent, Department of Gastroenterology, Ghent, Belgium;(2)Ghent University, VIB center for Inflammation Research IRC, Ghent, Belgium;(3)Ghent University, Department of Internal Medicine and Pediatrics, Ghent, Belgium;(4)KU Leuven, Department of Chronic Diseases- Metabolism and Ageing CHROMETA- Translational Research Center for Gastrointestinal Disorders TARGID, Leuven, Belgium;(5)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(6)Imelda General Hospital, Imelda GI Clinical Research Center, Bonheiden, Belgium;(7)AZ Maria Middelares, Department of Gastroenterology, Ghent, Belgium;(8)UZ Antwerp, Department of Gastroenterology, Antwerp, Belgium;(9)Erasme Hospital, Department of Gastroenterology, Brussels, Belgium;(10)AZ Sint-Lucas, St-Lucas IBD Clinic, Ghent, Belgium;(11)AZ Damiaan, Department of Gastroenterology, Oostende, Belgium;(12)CHU Liège University Hospital, Department of Gastroenterology, Liège, Belgium;(13)CHU UCL Namur, Department of Gastroenterology, Yvoir, Belgium;(14)UCL Saint Luc, Service d’Hépato-Gastroentérologie, Brussels, Belgium;(15)Saint-Pierre University Hospital Center - Université Libre de Bruxelles ULB, Department of Gastroenterology and Endoscopy, Brussels, Belgium;(16)AZ Nikolaas General Hospital, Department of Gastroenterology, Sint-Niklaas, Belgium;(17)Universitair Ziekenhuis Brussel UZ Brussel - Vrije Universiteit Brussel VUB, Department of Gastroenterology-Hepatology, Brussels, Belgium;(18)Wageningen University and Research, Nutrition- Metabolism and Genomics Group - Division of Human Nutrition and Health, Wageningen, Belgium;
OP29: Peripheral blood DNA methylation biomarkers accurately predict clinical- and endoscopic response to vedolizumab in a real-life cohort of Crohn’s Disease patientsECCO'22Year: 2022
Authors: Joustra, V.(1);Hageman, I.(1,2);Li Yim, A.(2,3);Levin, E.(4,5);Satsangi, J.(6);Adams, A.(6);De Jonge, W.(2);Henneman, P.(3);D'Haens, G.(1); on behalf of the EPIC consortium
(1)Amsterdam UMC- University of Amsterdam, Department of Gastroenterology & Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC- University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands;(3)Amsterdam UMC- University of Amsterdam, Genome Diagnostics Laboratory- Department of Clinical Genetics, Amsterdam, The Netherlands;(4)Horaizon, Bv, Delft, The Netherlands;(5)Amsterdam UMC- University of Amsterdam, Department of Vascular Medicine, Amsterdam, The Netherlands;(6)Oxford University- Hospitals NHS Foundation Trust- John Radcliffe Hospital, Translational Gastroenterology Unit- NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom;
OP30: Upadacitinib modulates inflammatory pathways in gut tissue in patients with Ulcerative Colitis: Transcriptomic profiling from the Phase 2b study, U-ACHIEVEECCO'22Year: 2022
Authors: Verstockt, B.(1);Blink Polakow, S.(2);Mahi, N.(2);Lee, J.(2);Wang, J.(3);Guay, H.(4);Salas, A.(5);Panés, J.(5);Ungaro, R.C.(6);Vermeire, S.(1);
(1)University Hospitals Leuven & KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)AbbVie Inc, Immunology, North Chicago, United States;(3)AbbVie Inc, Genomic Research Center, Cambridge, United States;(4)AbbVie Inc, Bioresearch Center, Worcester, United States;(5)Hospital Clinic de Barcelona, IDIBAPS CIBERehd, Barcelona, Spain;(6)The Mount Sinai Hospital, Icahn School of Medicine, New York, United States;
OP31: Dietary and Multi-Omic characterization of new onset treatment naive Crohn Disease identifies factors that may contribute to disease pathogenesisECCO'22Year: 2022
Authors: Haberman Ziv, Y.(1);Braun, T.(1);Amir, A.(1);Levhar , N.(1);Malik, A.(1);Neuman, S.(1);Picard, O.(1);Yavzuri, M.(1);Efroni, G.(1);Hadar, R.(1);Ben-Horin, S.(1);
(1)Tel-HaShomer Sheba Medical Center, Department of Pediatric Gastroenterology, Ramat Gan, Israel;for the Helmsley Charitable Trust SOURCE consortium investigators
OP33: Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programmeECCO'22Year: 2022
Authors: Colombel, J.F.(1);Cao, Q.(2);Ghosh, S.(3);Reinisch, W.(4);Zhou, W.(5);Ilo, D.(5);Shu, L.(5);Yao, X.(6);Rubin, D.T.(7);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(2)Sir Run Run Shaw Hospital- College of Medicine- Zhejiang University, Department of Gastroenterology, Hangzhou- Zhejiang, China;(3)University College Cork, College of Medicine and Health, Cork, Ireland;(4)Medical University of Vienna, Department of Gastroenterology and Hepatology, Vienna, Austria;(5)AbbVie Inc, Research and Development, North Chicago- Illinois, United States;(6)AbbVie Inc, Data & Statistical Sciences, North Chicago- Illinois, United States;(7)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago- Illinois, United States;
OP34: Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysisECCO'22Year: 2022
Authors: Panaccione, R.(1);Collins, E.B.(2);Melmed, G.Y.(3);Vermeire, S.(4);Danese, S.(5);Higgins, P.D.R.(6);Zhou, W.(7);Ilo, D.(7);Sharma, D.(7);Sanchez Gonzalez, Y.(7);Wang, S.T.(2);
(1)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;(2)Medicus Economics LLC, n/a, Milton, United States;(3)Cedars-Sinai Medical Center, n/a, Los Angeles, United States;(4)University Hospital Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)Gastroenterology and Endoscopy IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, n/a, Milan, Italy;(6)University of Michigan, Department of Medicine- Division of Gastroenterology, Ann Arbor, United States;(7)AbbVie Inc., n/a, North Chicago, United States;
OP35: Natural history of anal ulcerations in pediatric-onset Crohn's Disease: A population-based studyECCO'22Year: 2022
Authors: Mortreux, P.(1);Leroyer, A.(2);Dupont, C.(3);Ley, D.(4);Bertrand, V.(5);Spyckerelle, C.(6);Guillon, N.(2);Desreumaux, P.(1);Gower-Rousseau, C.(2);Savoye, G.(7);Fumery, M.(8);Turck, D.(4);Siproudhis, L.(9);Sarter, H.(2);
(1)CHU Lille, Gastro-enterology, Lille, France;(2)Lille 2 University- CHU Lille- EPIMAD Registry, Epidemiology Unit, Lille, France;(3)CHU Caen, Pediatric unit, Caen, France;(4)CHU Lille, Pediatric unit, Lille, France;(5)CH Le Havre, Pediatric unit, Le Havre, France;(6)GHICL, Pediatric unit, Lille, France;(7)CHU Rouen, Gastro-enterology, Rouen, France;(8)CHU Amiens, Gastro-enterology, Amiens, France;(9)CHU Rennes, Gastro-enterology, Rennes, France;EPIMAD
OP36: Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept studyECCO'22Year: 2022
Authors: Sands, B.E.(1);Feagan, B.G.(2);Sandborn, W.J.(3);Shipitofsky, N.(4);Marko, M.(4);Sheng, S.(4);Johanns, J.(4);Germinaro, M.(4);Vetter, M.(4);Panés, J.(5);
(1)Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States;(2)Robarts Research Institute, Western University, London, Canada;(3)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(4)Janssen Research & Development- LLC, Immunology, Spring House, United States;(5)Hospital Clínic de Barcelona, Gastroenterology, Barcelona, Spain;VEGA
OP37: Bacterial suppression of intestinal fungi via activation of human gut Vδ2+ T-cellsECCO'22Year: 2022
Authors: Mathew, L.(1);Savage, M.(1);Pardieu, C.(1);O'Brien, M.(1);Sze, S.K.(2);Eberl, M.(3);Stagg, A.(1);Gasparetto, M.(4);Kok, K.(4);Lindsay, J.(4);McCarthy, N.(1);
(1)Barts and The London- Queen Mary's School of Medicine and Dentistry, The Blizard Institute- Centre for Immunobiology, London, United Kingdom;(2)Brock University, Department of Health Sciences, St. Catharines, Canada;(3)Cardiff University, Division of Infection and Immunity, Cardiff, United Kingdom;(4)Bart's Health NHS Trust, Department of Gastroenterology, London, United Kingdom;
OP38: Tofacitinib for the treatment of Ulcerative Colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trialsECCO'22Year: 2022
Authors: Sandborn, W.J.(1);D'Haens, G.R.(2);Sands, B.E.(3);Panaccione, R.(4);Ng, S.C.(5);Lawendy, N.(6);Kulisek, N.(6);Guo, X.(6);Mundayat, R.(7);Su, C.(7);Panés, J.(8);
(1)University of California San Diego, Division of Gastroenterology, La Jolla- CA, United States;(2)Amsterdam University Medical Centres, Department of Gastroenterology, Amsterdam, The Netherlands;(3)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York- NY, United States;(4)University of Calgary, Division of Gastroenterology and Hepatology- Department of Medicine, Calgary- AB, Canada;(5)LKS Institute of Health Science- Chinese University of Hong Kong, Institute of Digestive Disease- Department of Medicine and Therapeutics, Hong Kong, China;(6)-, Pfizer Inc, Collegeville- PA, United States;(7)-, Pfizer Inc, New York- NY, United States;(8)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Department of Gastroenterology, Barcelona, Spain;
